SKI Market

Indian Indices

Sensex

82,470.81 -27.33
( -0.03%)

Global Indices

Nasdaq

49,410.74 -272.93
(-0.55%)

Dow Jones

6,881.90 -20.41
(-0.30%)

Hang Seng

57,519.13 375.29
(0.66%)

Nikkei 225

10,620.33 -65.85
(-0.62%)

Forex

USD-INR

90.70 0.01
(0.01%)

EUR-INR

107.23 -0.14
(-0.13%)

GBP-INR

122.83 -0.27
(-0.22%)

JPY-INR

0.59 0.00
(-0.51%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

ERIS Lifesciences Ltd

Industry : Pharmaceuticals - Indian - Formulations

BSE Code

ISIN Demat

Book Value()

540596

INE406M01024

230.5682287

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

ERIS

18414.59

EPS(TTM)

Face Value()

Div & Yield %

21.44

0.54

Back

Glaxosmithkline Pharmaceuticals consolidated net profit rises 28.60% in the December 2025 quarter

Feb 09,2026

Net profit of Glaxosmithkline Pharmaceuticals rose 28.60% to Rs 295.62 crore in the quarter ended December 2025 as against Rs 229.88 crore during the previous quarter ended December 2024. Sales rose 9.67% to Rs 1041.26 crore in the quarter ended December 2025 as against Rs 949.42 crore during the previous quarter ended December 2024.

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	1041.26	949.42	10
OPM %	35.66	30.75	-
PBDT	402.27	326.90	23
PBT	381.95	308.10	24
NP	295.62	229.88	29

82,470.81 -27.33 ( -0.03%)

49,410.74 -272.93 (-0.55%)

6,881.90 -20.41 (-0.30%)

57,519.13 375.29 (0.66%)

10,620.33 -65.85 (-0.62%)

90.70 0.01 (0.01%)

107.23 -0.14 (-0.13%)

122.83 -0.27 (-0.22%)

0.59 0.00 (-0.51%)